Daiichi Sankyo Company, Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hiroyuki Okuzawa
- Full Time Employees
- 20,171
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Daiichi Sankyo Building A/B Tokyo TY Japan 103-8426
- IPO Date
- Sep 28, 2005
- Website
- daiichisankyo.co.jp
- Similar Companies
- Business
- Daiichi Sankyo Company, Limited (4568.T) is a global pharmaceutical company focused on the research, development, manufacture, and commercialization of innovative medicines, primarily in oncology, cardiovascular-metabolic diseases, and other therapeutic areas. The company offers a portfolio of prescription pharmaceuticals including Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate for HER2-positive and HER2-low breast cancer and other solid tumors; Vanflyta (quizartinib) for acute myeloid leukemia; Edoxaban for thrombosis prevention; prasugrel for antiplatelet therapy; olmesartan-based antihypertensives; and other products such as Pregabalin, ezalutamide, and Belsomra for insomnia; as well as a pipeline of antibody-drug conjugates (ADCs) like datopotamab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan targeting various cancers, alongside investigational assets including DS-3610 immunotherapy and MK-6070 in collaboration with Merck. Headquartered in Tokyo, Japan, at 3-5-1 Nihonbashi-honcho, Chuo-ku, the company was founded on September 28, 2005, through the merger of Daiichi Pharmaceutical and Sankyo, and operates in more than 30 countries/regions worldwide, including subsidiaries in the U.S. (Basking Ridge, New Jersey), Europe (Munich, Germany headquarters), Canada, and manufacturing sites such as Pfaffenhofen, Germany. In recent developments, Daiichi Sankyo announced a approximately EUR 1 billion expansion of its Pfaffenhofen facility in 2024 into an international innovation center for antibody-drug conjugates and cardiovascular production; partnered with General Proximity for a drug discovery platform targeting undruggable cancer proteins; expanded its strategic collaboration with Merck to include MK-6070, a DXd-ADC for co-development and co-promotion globally excluding Japan; obtained a new indication for Ezalmya and took over marketing of Belsomra from MSD in Japan; advanced DS-3610 into human trials; and initiated exploratory studies for raludotatug deruxtecan beyond ovarian cancer into lung and gastrointestinal cancers, supporting FY2025 revenue guidance of 2 trillion yen driven by oncology growth.
Company News
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up on Analyst Upgrade
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
Daiichi Sankyo Company, Limited (DSNKY) Q1 2027 Earnings Call Transcript
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
Daiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast
Daiichi Sankyo: Not Exciting Enough For This Market, Apparently
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase